Thromb Haemost 1989; 61(01): 043-049
DOI: 10.1055/s-0038-1646524
Original Article
Schattauer GmbH Stuttgart

R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - II. Pharmacological Effects In Vivo and Ex Vivo

F De Clerck
The Department of Haematology, Janssen Research Foundation, Beerse, Belgium
,
J Beetens
The Department of Haematology, Janssen Research Foundation, Beerse, Belgium
,
A Van de Water
1   The Department of Cardiovascular Pharmacology, Janssen Research Foundation, Beerse, Belgium
,
E Vercammen
2   The Department of Clinical Research, Janssen Research Foundation, Beerse, Belgium
,
P A J Janssen
The Department of Haematology, Janssen Research Foundation, Beerse, Belgium
› Author Affiliations
Further Information

Publication History

Received 25 April 1988

Accepted after revision 05 October 1988

Publication Date:
24 July 2018 (online)

Preview

Summary

R 68 070 or (E)-5-[[[(3-pyridinyl)[3-(trifluoromethyl)phenyl]- methylen]amino]oxy] pentanoic acid (Janssen Research Foundation, Belgium), a newly developed compound, combining specific thromboxane A2 (TXA2) synthetase inhibition with TXA2/pros- taglandin endoperoxide receptor blockade in one molecule, is active in vivo in man and in experimental animals.

In man (n = 5), a single oral 400-mg dose of R 68 070 produces deep and protracted inhibition of platelet TXA2 synthetase activity (≥90% for 48 h), increases serum levels of immuno- reactive 6-keto-PGF, reduces platelet aggregation in RR.R induced by U 46619, collagen (>70% for 8 h), arachidonic acid (>90% for 18 h) and prolongs template bleeding times significantly, without affecting plasma coagulation or fibrinolysis.

In rats, R 68 070 (1.25 mg/kg orally, –2 h) singly prolongs tail bleeding times as much as a combination of TXA2 synthetase inhibition (dazoxiben 10 mg/kg) and TXA2/prostaglandin endoperoxide receptor blockade (BM 13177 40 mg/kg). In dogs, the compound reduces coronary thrombosis induced by electrical damage (1.25 mg/kg i. v.) and prevents the evolution of occlusion/ reperfusion-induced arrhythmias into ventricular fibrillation (2.5 mg/kg i.v.). R 68 070 thus may be an appropriate pharmacological tool to analyze the roles and interactions of agonistic (TXA2, prostaglandin endoperoxides) and antagonistic (PGD2, PGE2, PGI2) metabolites of arachidonic acid in experimental and human pathologies.